截至2026年2月27日收盘，鹿得医疗（920278）报收于9.51元，较前一交易日下跌1.25%，最新总市值为 16.59亿元。该股当日开盘9.63元，最高9.65元，最低9.47元，成交额达1602.88万元，换手率为2.27%。 《2025年年度业绩快报》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司于2026年2月27日披露《2025年年度业绩快报》。公告显示，报告期内营业总收入为300,328,058.66 元，同比下降12.85%；归属于上市公司股东的净利润为18,913,373.29元，同比下降31.33%；扣除非经常 性损益后的净利润为16,662,834.86元，同比下降36.42%。基本每股收益为0.11元，同比下降31.33%。报 告期末总资产为589,226,940.16元，同比增长11.27%；归属于上市公司股东的所有者权益为 383,776,435.86元，同比下降4.00%。 最新公告列表 ...

证券日报网讯 2月27日，鹿得医疗发布公告称，公司2025年实现营业总收入预计为300328058.66元，同 比下降12.85%；归属于上市公司股东的净利润预计为18913373.29元，同比下降31.33%。 （文章来源：证券日报） ...

（记者 曾健辉） 每经讯，鹿得医疗2月27日发布公告称，2025年，公司营业收入为3亿元，上年同期为3.45亿元，同比下 降12.85%。归属于上市公司股东的净利润为1891万元，上年同期为2754万元，同比下降31.33%。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

Company Performance - The company has not yet announced its full-year financial data for 2025, with an annual report expected to be released in early 2026. The Q3 2025 report shows revenue of 216.5 million and a net profit of 17.69 million, with attention needed on whether losses will further narrow and the recovery of overseas sales [2]. Industry Policy and Environment - The national "14th Five-Year Plan" clearly supports the development of innovative drugs and medical devices, with the smart home medical device market expected to exceed 90 billion by 2026. This policy may provide growth opportunities for the company's products, such as blood pressure monitors and nebulizers. However, international geopolitical conflicts have impacted overseas revenue, which saw a year-on-year decline of 9.72% in the first half of 2025 [3]. Company Business Status - The company primarily focuses on overseas markets, with 87.42% of its revenue coming from international sales in 2019. Attention is needed on the expansion of cross-border e-commerce and the operational efficiency of the "Lude Medical Health Smart Industry Park Project." The H1 2025 report indicates that the company is promoting lean management and optimizing production lines to enhance capacity utilization [4].

Group 1 - Three-dimensional Communication, Kaichun Co., Ltd., and Jiuqi Software reached the daily limit increase in stock prices, indicating strong market interest [1] - Worth Buying, BlueFocus Communication Group, Aofei Data, Hengyi Petrochemical, and Lude Medical also experienced stock price increases, suggesting a broader positive trend in the market [1]

Core Viewpoint - The medical device sector experienced a decline of 1.58% on January 16, with Kangzhong Medical leading the losses, while the Shanghai Composite Index fell by 0.26% and the Shenzhen Component Index decreased by 0.18% [1]. Group 1: Market Performance - The medical device sector's stocks showed mixed performance, with notable gainers including Huakang Clean (20.01% increase) and Yirui Technology (4.60% increase) [1]. - Conversely, Kangzhong Medical saw a significant drop of 8.60%, followed by Huada Zhizao with a decline of 6.61% [2]. - The overall trading volume in the medical device sector was substantial, with Huakang Clean achieving a transaction amount of 707 million yuan [1]. Group 2: Capital Flow - The medical device sector experienced a net outflow of 1.395 billion yuan from major funds, while retail investors contributed a net inflow of 1.42 billion yuan [2]. - Specific stocks like Huakang Clean had a net inflow of 58.17 million yuan from major funds, while retail investors showed a net outflow of 46.88 million yuan [3]. - The capital flow dynamics indicate a shift in investor sentiment, with retail investors actively participating despite the overall sector decline [2][3].

Group 1 - The medical device sector increased by 0.66% on January 14, with Sanyou Medical leading the gains [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] - Notable gainers in the medical device sector included Sanyou Medical, which rose by 16.63% to a closing price of 22.30, and Tianzhihang, which increased by 13.25% to 24.95 [1] Group 2 - The medical device sector experienced a net outflow of 428 million yuan from institutional investors and 495 million yuan from retail investors, while retail investors saw a net inflow of 923 million yuan [2] - The individual stock fund flow data indicated that Yuyue Medical had a net inflow of 356 million yuan from institutional investors, while it faced a net outflow of 66.06 million yuan from retail investors [3] - Other companies like Yingke Medical and Weili Medical also showed significant net inflows from institutional investors, with 105 million yuan and 90.06 million yuan respectively [3]

Group 1 - The stock price of Lude Medical (920278) closed at 10.2 yuan on January 12, 2026, with an increase of 5.92% and a turnover rate of 21.14%, resulting in a trading volume of 156,500 shares and a transaction amount of 155 million yuan [1] - On January 12, 2026, the net inflow of main funds was 18.02 million yuan, accounting for 11.61% of the total transaction amount, while retail investors had a net outflow of 2.22 million yuan, representing 1.43% of the total transaction amount [1][3] - The company held its 13th meeting of the 4th Board of Directors on January 9, 2026, where it approved the postponement of the "Lude Medical Health Smart Industrial Park" fundraising project without changing the total investment amount or the use of raised funds [1] Group 2 - The "Lude Medical Health Smart Industrial Park" project has been delayed from the original expected completion date of February 7, 2026, to June 30, 2027, due to economic conditions and market demand [2][3] - As of December 31, 2025, the project had accumulated an investment of approximately 85.25 million yuan, with an investment progress of 72.81% [2]

Group 1 - The core point of the article is that Lude Medical (920278) has experienced a stock price increase of 5.92% to 10.2 yuan, with a total market capitalization of 1.78 billion yuan as of January 12, 2026 [1] - The stock opened at 9.81 yuan, reached a high of 10.24 yuan, and a low of 9.54 yuan, with a trading volume of 1.55 billion yuan and a turnover rate of 21.14% [1] - Lude Medical announced a delay in the construction progress of its "Lude Medical Health Smart Industrial Park" project due to economic conditions and market demand, pushing the expected completion date from February 7, 2026, to June 30, 2027 [1] - As of December 31, 2025, the project has utilized 85,249,547.09 yuan of raised funds, achieving an investment progress of 72.81% [1] - The decision regarding the project delay has been approved by the board of directors and relevant committees, with no objections from the sponsoring institution [1]

Core Viewpoint - The company, Jiangsu Lude Medical Electronics Co., Ltd., has announced its expected daily related transactions for 2026, amounting to 6.7 million yuan, which includes various procurement and leasing activities [1]. Group 1: Stock Performance - As of December 23, 2025, Lude Medical's stock closed at 9.71 yuan, down 3.09% from the previous trading day [1]. - The stock opened at 9.96 yuan, reached a high of 10.16 yuan, and a low of 9.55 yuan, with a trading volume of 1.39 billion yuan and a turnover rate of 19.08% [1]. Group 2: Related Transactions - The company expects to engage in related transactions totaling 6.7 million yuan in 2026 [1]. - Specific transactions include purchasing goods from Shanghai Beirui Electronic Technology Co., Ltd. for 4 million yuan and selling products for 2 million yuan [1]. - Additionally, the company plans to procure components from Wenzhou Naikang Protective Products Co., Ltd. for 4 million yuan and lease office space from related parties for 700,000 yuan [1]. - The pricing for these related transactions will follow market fairness principles and will not affect the company's independence [1]. - The board of directors has approved this matter, and it does not require submission to the shareholders' meeting for approval [1].